Diamyd Medical announced that the company's Board of Directors has appointed Ulf Hannelius, PhD, MBA, to new CEO. Ulf Hannelius (40), PhD in molecular biology from Karolinska Institute and with an MBA from Stockholm School of Economics has been appointed to assumes, the position as CEO of Diamyd Medical.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.76 SEK | -1.18% | -1.67% | +79.00% |
05-16 | Diamyd Medical AB Updates on the Registrational Phase 3 Trial | CI |
04-18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.00% | 111M | |
+11.04% | 115B | |
+12.61% | 106B | |
-4.22% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.15% | 17.56B | |
-40.50% | 17.32B | |
+6.47% | 14.03B | |
+31.72% | 12.13B |
- Stock Market
- Equities
- DMYD B Stock
- News Diamyd Medical AB
- Diamyd Medical Appoints Ulf Hannelius as New CEO